C
KROS icon

Covestor’s Keros Therapeutics KROS Stock Holding History

Covestor’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2K Buy
162
+112
+224% +$1.25K ﹤0.01% 1978
2026
Q1 		$1K Buy
50
+45
+900% +$695 ﹤0.01% 2073
2025
Q4 		$0 Sell
5
-3,502
-100% -$61.4K ﹤0.01% 2508
2025
Q3 		$55K Sell
3,507
-5,842
-62% -$86.3K 0.03% 863
2025
Q2 		$125K Sell
9,349
-7,712
-45% -$104K 0.07% 421
2025
Q1 		$174K Buy
17,061
+15,779
+1,231% +$183K 0.12% 200
2024
Q4 		$20K Buy
1,282
+1,280
+64,000% +$66.5K 0.01% 1188
2024
Q3 		$0 Hold
2
– – ﹤0.01% 2477
2024
Q2 		$0 Hold
2
– – ﹤0.01% 2496
2024
Q1 		$0 Sell
2
-5
-71% -$296 ﹤0.01% 2494
2023
Q4 		$0 Buy
7
+4
+133% +$125 ﹤0.01% 2427
2023
Q3 		$0 Hold
3
– – ﹤0.01% 2410
2023
Q2 		$0 Hold
3
– – ﹤0.01% 2402
2023
Q1 		$0 Hold
3
– – ﹤0.01% 2311
2022
Q4 		$0 Hold
3
– – ﹤0.01% 2335
2022
Q3 		$0 Sell
3
-1
-25% -$35 ﹤0.01% 2303
2022
Q2 		$0 Sell
4
-1
-20% -$44 ﹤0.01% 2142
2022
Q1 		$0 Buy
+5
New +$257 ﹤0.01% 2278

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Covestor's KROS Position: Q2 2026 in Review

Covestor increased its Keros Therapeutics (KROS) stake by 224% in Q2 2026, buying an estimated $1.25K and bringing the position to 162 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1978.

Covestor first reported a position in KROS in Q1 2022 and has held it in 18 quarters since. The position peaked at $174K in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Covestor held 162 shares of Keros Therapeutics worth $2K as of Q2 2026.
  • Covestor bought 112 Keros Therapeutics shares in Q2 2026, an estimated $1.25K.
  • Keros Therapeutics made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #1978 holding.
  • Covestor first reported a position in Keros Therapeutics in Q1 2022 and has held it in 18 quarters since.
  • Covestor's Keros Therapeutics position peaked at $174K in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.